Nairem (Tadalafil)

Tadalafil, the active ingredient in Nairem, is a phosphodiesterase type 5 inhibitor presented as an oral tablet for systemic use. It treats erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension in adult patients.

GNH USA supplies Nairem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality assurance processes and regulatory approvals across EU and other markets. Our distribution network ensures timely delivery and compliance with local import requirements. We partner with accredited logistics providers to maintain product integrity during transit.

Tadalafil acts on the phosphodiesterase type 5 pathway to improve blood flow in specific vascular conditions. - Erectile dysfunction: improves ability to achieve and maintain an erection during sexual activity. - Benign prostatic hyperplasia: reduces urinary symptoms such as urgency and weak stream. - Pulmonary arterial hypertension: enhances exercise capacity by lowering pulmonary arterial pressure.

Tadalafil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Flushing: warmth and redness of the face or neck. - Dyspepsia: upset stomach or indigestion. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Sudden vision loss: abrupt loss of vision in one or both eyes (non‑arteritic anterior ischemic optic neuropathy). - Priapism: prolonged erection lasting more than four hours. - Severe hypotension: marked drop in blood pressure, especially with nitrates.

Before prescribing tadalafil, consider the following precautions to ensure safe use. - Cardiovascular assessment: evaluate patients with recent heart attack, unstable angina, or severe heart failure. - Nitrate use: avoid concurrent use with nitrates or nitric‑oxide donors due to risk of severe hypotension. - Alpha‑blocker therapy: monitor blood pressure when combined with alpha‑blockers. - Visual disorders: caution in patients with retinal diseases such as retinitis pigmentosa. - Hepatic or renal impairment: dose adjustment may be required in moderate to severe impairment. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Tadalafil can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): can cause dangerous drops in blood pressure. - Guanylate cyclase stimulators (e.g., riociguat): may lead to severe hypotension. - Unregulated herbal products containing PDE5 inhibitors: increase risk of toxicity.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may cause additive blood pressure lowering. - Antihypertensives (e.g., ACE inhibitors, beta‑blockers): monitor for enhanced hypotensive effect. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise tadalafil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.